Piscataway, NJ, April 21, 2023–Camber Pharmaceuticals is pleased to announce the addition of Roflumilast 250 mcg Tablets to its current portfolio.
Roflumilast Tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD, associated with chronic bronchitis and a history of exacerbations.
Roflumilast 250 mcg Tablets are available in 20 and 28 unit-dose cartons.
Roflumilast Tablets are also available in 500 mcg strength in 30 and 90 count bottles.
To find out more about Roflumilast Tablets please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
